Dyne Therapeutics, Inc. (DYN) News
Filter DYN News Items
DYN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest DYN News From Around the Web
Below are the latest news stories about DYNE THERAPEUTICS INC that investors may wish to consider to help them evaluate DYN as an investment opportunity.
3 of the Best Cheap Stocks Under $20 to Buy Now: November EditionAfter dropping to 52-week lows, the markets have been rallying, sending traders and investors are looking for cheap stocks under $20. |
Dyne Therapeutics to Present at November Investor ConferencesWALTHAM, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to present at the following investor conferences in November: Stifel 2023 Healthcare Conference, fireside chat on Tuesday, November 14, 2023 at 4:45 p.m. ET in New York Piper Sandler 35th Annual Healthcare Confe |
Dyne Therapeutics Inc (DYN) Reports Q3 2023 Financial Results and Progress in Clinical TrialsCompany's cash position remains strong, R&D expenses increase, and net loss widens |
The Dyne Therapeutics Inc (DYN) Company: A Short SWOT AnalysisUnveiling the Strengths, Weaknesses, Opportunities, and Threats of Dyne Therapeutics Inc |
Dyne Therapeutics Reports Third Quarter 2023 Financial Results and Provides Update on Significant Progress for ACHIEVE and DELIVER Trials and Upcoming Clinical Milestones- Initial ACHIEVE and DELIVER Data to be Presented at a Company Event Around the J.P. Morgan Healthcare Conference in Early January 2024, Including Safety, Biomarker of Splicing and Functional Outcome of Myotonia in DM1; Safety and Dystrophin Expression in DMD - - ACHIEVE Trial of DYNE-101 in DM1 Fully Enrolled Through 3.4 mg/kg Cohort;DELIVER Trial of DYNE-251 in DMD Fully Enrolled Through 10 mg/kg Cohort - - Safety Profile in ACHIEVE and DELIVER Has Supported Dose Escalation to a Combined Nine |
We Think Dyne Therapeutics (NASDAQ:DYN) Needs To Drive Business Growth CarefullyJust because a business does not make any money, does not mean that the stock will go down. For example, biotech and... |
Dyne Therapeutics to Present at October Investor ConferencesWALTHAM, Mass., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to present at the following investor conferences in October: Chardan’s 7th Annual Genetic Medicines Conference, fireside chat on Tuesday, October 3, 2023 at 11:00 a.m. ET in New York Jefferies Inaugural Biotech |
Dyne Therapeutics Receives FDA Orphan Drug Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1- On Track to Report Initial Data from the Global, Multiple Ascending Dose Phase 1/2 ACHIEVE Clinical Trial in the Second Half of 2023 - WALTHAM, Mass., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for DYNE-101 for |
Why Shares of Dyne Therapeutics Fell This WeekThe clinical-stage biotech's stock closed at $10.98 last week, then fell to as low as $8.57 this Friday, thanks to a number of insiders selling their shares. On Wednesday the company released six filings with the Securities and Exchange Commission (SEC), all showing selling by company executives on Tuesday. According to the filings, president and CEO Joshua Brumm sold 7,622 shares, chief operating officer Susanna High sold 1,635 shares, chief medical officer Wildon Farwell sold 1,707 shares, chief scientific officer Oxana Beskrovnaya sold 1,484 shares, chief business officer Jonathan McNeill sold 1,266 shares, and senior vice president Richard Scalzo sold 1,397 shares. |
Insider Sell: Chief Medical Officer Wildon Farwell Sells 1,707 Shares of Dyne Therapeutics IncOn September 12, 2023, Wildon Farwell, the Chief Medical Officer of Dyne Therapeutics Inc (NASDAQ:DYN), sold 1,707 shares of the company. |